Organization profile

DMSP is the result of the collaboration between the Luxembourg Centre for Systems Biomedicine at the University of Luxembourg (LCSB/UL) and LIH. The platform combines the cellular disease modelling expertise of both institutions with early drug discovery technology.  

  

The ultimate objective of the DMSP is to provide a diversity of core facilities infrastructure, disease models and expertise, to facilitate the translation of basic scientific discoveries into tangible hit (drug) candidates. Our state-of-the-art platform acts as interface between fundamental biomedical research and high standard drug discovery:  

  

  • to help researchers to develop screenings based on their biological findings  
  • to perform High Throughput Screenings (HTS) for them with our compounds or their own library  
  • to develop new cellular disease models for phenotypic screening (HCS)  
  • to offer phenotypic screenings in established patient-derived cellular models  

Fingerprint

Dive into the research topics where Disease Modeling & Screening Platform is active. These topic labels come from the works of this organisation's members. Together they form a unique fingerprint.

Network

Recent external collaboration on country/territory level. Dive into details by clicking on the dots or